Get started
Work

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Year: 2018
Type: conference-abstract
Source: Blood
DOI: 10.1182/blood-2018-99-115241
Authors: Steven M. Horwitz, Alison J. Moskowitz, Eric D Jacobsen, Neha Mehta-Shah, Michael S Khodadoust, David C. Fisher, Patricia Myskowski, Erica B.K. Wang, Marianne Tawa, Theresa Davey, William Blouin, Helen Hancock, Nivetha Ganesan, Natasha Galasso, Evan Marzouk, Alexandra Bahgat, Hallie Jester, Sophia Fong, Abeer Butt, Ahmet Dogan, Youn H. Kim, David M Weinstock
Institutions: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Washington University in St. Louis, Stanford Cancer Institute, Stanford University, Harvard University, Dana-Farber/Harvard Cancer Center
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W2908502623
Cites:
Cited by: 40
Related to: 10